Brigitte Sigal-Zafrani

Paris, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 98 publications

COX2/PTGS2 Expression Is Predictive of Response to Neoadjuvant Celecoxib in HER2-negative Breast Cancer Patients.

COX2/PTGS2 Expression Is Predictive of Response to Neoadjuvant Celecoxib in HER2-negative Breast Cancer Patients.

Journal: Anticancer research

Published: December 05, 2017

Long-term outcome of the REMAGUS 02 trial, a multicenter randomised phase II trial in locally advanced breast cancer patients treated with neoadjuvant chemotherapy with or without celecoxib or trastuzumab according to HER2 status.

Long-term outcome of the REMAGUS 02 trial, a multicenter randomised phase II trial in locally advanced breast cancer patients treated with neoadjuvant chemotherapy with or without celecoxib or trastuzumab according to HER2 status.

Journal: European journal of cancer (Oxford, England : 1990)

Published: December 22, 2016

Genetic Heterogeneity in Therapy-Naïve Synchronous Primary Breast Cancers and Their Metastases.

Genetic Heterogeneity in Therapy-Naïve Synchronous Primary Breast Cancers and Their Metastases.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: December 11, 2016

Gain-of-function Prolactin Receptor Variants Are Not Associated With Breast Cancer and Multiple Fibroadenoma Risk.

Gain-of-function Prolactin Receptor Variants Are Not Associated With Breast Cancer and Multiple Fibroadenoma Risk.

Journal: The Journal of clinical endocrinology and metabolism

Published: August 31, 2016

BIRC5 (survivin): a pejorative prognostic marker in stage II/III breast cancer with no response to neoadjuvant chemotherapy.

BIRC5 (survivin): a pejorative prognostic marker in stage II/III breast cancer with no response to neoadjuvant chemotherapy.

Journal: Breast cancer research and treatment

Published: June 13, 2016

Medico-economic impact of MSKCC non-sentinel node prediction nomogram for ER-positive HER2-negative breast cancers.

Medico-economic impact of MSKCC non-sentinel node prediction nomogram for ER-positive HER2-negative breast cancers.

Journal: PloS one

Published: March 20, 2016

Randomized phase 2 neoadjuvant trial evaluating anastrozole and fulvestrant efficacy for postmenopausal, estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients: Results of the UNICANCER CARMINA 02 French trial (UCBG 0609).

Randomized phase 2 neoadjuvant trial evaluating anastrozole and fulvestrant efficacy for postmenopausal, estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients: Results of the UNICANCER CARMINA 02 French trial (UCBG 0609).

Journal: Cancer

Published: January 28, 2016

Characterization of Breast Cancer Preclinical Models Reveals a Specific Pattern of Macrophage Polarization.

Characterization of Breast Cancer Preclinical Models Reveals a Specific Pattern of Macrophage Polarization.

Journal: PloS one

Published: October 12, 2015

Estrogen-Receptor, Progesterone-Receptor and HER2 Status Determination in Invasive Breast Cancer. Concordance between Immuno-Histochemistry and MapQuant™ Microarray Based Assay.

Estrogen-Receptor, Progesterone-Receptor and HER2 Status Determination in Invasive Breast Cancer. Concordance between Immuno-Histochemistry and MapQuant™ Microarray Based Assay.

Journal: PloS one

Published: September 07, 2015

Identifying trajectory clusters in breast cancer survivors' supportive care needs, psychosocial difficulties, and resources from the completion of primary treatment to 8 months later.

Identifying trajectory clusters in breast cancer survivors' supportive care needs, psychosocial difficulties, and resources from the completion of primary treatment to 8 months later.

Journal: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer

Published: March 09, 2015

Genomic hallmarks of homologous recombination deficiency in invasive breast carcinomas.

Genomic hallmarks of homologous recombination deficiency in invasive breast carcinomas.

Journal: International journal of cancer

Published: January 14, 2015

Breast cancer survivors' perceived medical communication competence and satisfaction with care at the end of treatment.

Breast cancer survivors' perceived medical communication competence and satisfaction with care at the end of treatment.

Journal: Psycho-oncology

Published: December 05, 2014

Showing 1-12 of 98

Last Updated: 09/26/2026